샘플 요청 목록

 카트 문의
시장보고서
상품코드
1551649

세계의 간세포암 치료제 시장

Hepatocellular Carcinoma Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 198 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

간세포암 치료제 세계 시장, 2030년까지 17억 달러에 달할 것으로 전망

2023년 11억 달러로 추정되는 간세포암 치료제 세계 시장은 2023-2030년의 분석 기간 동안 연평균 6.1% 성장하여 2030년에는 17억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 화학요법 치료는 CAGR 7.2%를 기록하여 분석 기간 종료 시점에 6억 6,480만 달러에 도달할 것으로 예상됩니다. 항암 화학요법 치료 분야의 성장률은 분석 기간 동안 CAGR 6.2%로 추정됩니다.

미국 시장은 약 2억 9,740만 달러, 중국은 CAGR 10.1%로 성장할 것으로 예상

미국의 간세포암 치료제 시장은 2023년 2억 9,740만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 3억 5,860만 달러 규모에 도달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 10.1%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 2.5%와 6.2%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 연평균 3.8%의 성장률을 보일 것으로 예상됩니다.

세계 간세포암 치료제 시장 - 주요 동향 및 촉진요인 정리

간세포암 치료제의 최신 동향은?

원발성 간암 중 가장 흔한 유형인 간세포암(HCC)은 최근 몇 년동안 약물 개발이 크게 진전되어 환자들에게 새로운 희망을 가져다주고 있습니다. 간세포암에 대한 기존의 치료 옵션은 수술, 간이식, 고주파 소작술이나 경동맥 화학색전술과 같은 국소 치료로 거의 한정되어 있었습니다. 그러나 분자표적치료제와 면역치료제의 등장으로 치료 환경이 바뀌었고, FDA가 최초로 승인한 간세포암 표적치료제인 소라페닙은 종양세포의 증식과 혈관신생을 억제함으로써 획기적인 전환점을 마련하였습니다. 이후 렌바티닙, 레고라페닙, 카보잔티닙과 같은 새로운 약물이 등장해 생존율과 내약성이 개선됐습니다. 또한 니볼루맙, 펨브롤리주맙과 같은 면역관문억제제의 도입으로 특히 수술 적응증이 없는 환자나 진행 단계의 환자들에게 더 많은 치료 옵션을 제공했습니다. 이들 치료제는 암세포에 대한 신체의 면역반응을 강화하는 방식으로 작용하며, 기존 접근법을 보완하는 새로운 작용기전을 제공합니다. 간세포암 치료제의 끊임없는 진화는 환자의 예후를 개선하기 위한 지속적인 연구와 임상시험의 중요성을 강조하고 있습니다.

병용요법은 간세포암 치료 패러다임을 어떻게 바꾸고 있는가?

단독요법의 효과와 지속성에 한계가 있다는 인식에 따라, 병용요법이 간세포암 치료의 근간이 되고 있습니다. 표적치료제와 면역치료의 병용요법은 특히 치료 옵션이 제한적이었던 진행성 간세포암에서 유망한 결과를 보여주고 있습니다. 예를 들어, 면역관문억제제인 아테졸리주맙과 항VEGF 항체인 베바시주맙의 병용요법은 소라페닙과 비교하여 우수한 효능을 보여 절제 불가능한 간세포암의 1차 치료의 새로운 표준 치료법이 되었습니다. 이 병용요법은 면역조절과 혈관신생 억제의 시너지 효과를 이용하여 생존기간을 연장하고 병의 진행을 억제할 수 있습니다. 마찬가지로, 현재 진행 중인 임상시험에서는 이중 체크포인트 억제제(예: 니볼루맙과 이필리무맙 병용), 면역 체크포인트 억제제와 티로신 키나아제 억제제를 병용하는 등 다양한 병용 요법이 검토되고 있습니다. 이러한 병용 전략의 성공은 특히 HCC와 같이 복잡하고 불균일한 질병에서 내성 메커니즘을 극복하고 보다 지속적인 반응을 달성할 수 있는 가능성을 강조하고 있습니다. 연구가 진행됨에 따라 병용요법은 치료 환경을 더욱 변화시켜 HCC 환자들에게 보다 개인화되고 효과적인 치료 옵션을 제공할 수 있을 것으로 기대됩니다.

간세포암 치료제 개발의 과제와 기회는?

간세포암 치료제 개발은 몇 가지 문제에 직면해 있지만 동시에 혁신과 진보를 위한 큰 기회이기도 합니다. 주요 과제 중 하나는 질병의 불균일성입니다. 간세포암은 B형 및 C형 간염 감염, 비알코올성 지방간염(NASH), 간경변증 등 다양한 간 기저 질환에서 발생할 수 있으며, 각 질환은 치료에 대한 반응이 다릅니다. 이러한 다양성으로 인해 획일적인 치료법 개발이 어려우며, 보다 맞춤 치료 접근법이 필요합니다. 또한, 간세포암 환자들은 간 기능이 저하된 경우가 많기 때문에 약물 대사에 있어 간의 중심적인 역할은 효과적이고 안전한 치료법을 개발하는 데 있어 또 다른 도전이 될 수 있습니다. 이러한 어려움에도 불구하고, 특히 바이오마커 발굴과 정밀의료 분야에서는 기술 혁신의 큰 기회가 있습니다. 치료 반응을 예측할 수 있는 분자 마커를 찾아내면 치료 효과를 높이고 부작용을 최소화할 수 있는 보다 표적화된 치료 접근이 가능해집니다. 또한, 장간축을 활용하여 간세포암의 진행에 있어 마이크로바이옴의 역할을 탐구하는 것에 대한 관심이 증가하고 있으며, 이는 치료 개입의 새로운 길을 제시하고 있습니다. 이러한 과제와 기회는 유전체학, 면역학, 약리학의 발전을 통합하는 간세포암 치료제 개발에 대한 다학제적 접근의 필요성을 강조하고 있습니다.

간세포암 치료제 시장의 성장 원동력은?

간세포암 치료제 시장의 성장은 의료 기술의 발전, 의료 관행의 변화, 환자층의 변화를 반영하는 몇 가지 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 C형 간염, B형 간염, 비알코올성 지방간 질환(NAFLD)과 같은 만성 간 질환의 발병률 증가에 힘입어 전 세계적으로 간세포암 발생률이 증가하고 있다는 점입니다. 이러한 환자 수 증가는 효과적인 치료 옵션에 대한 수요를 증가시키고 있습니다. 또한, 생명공학 기술의 급속한 발전과 새로운 약물 전달 시스템의 개발은 간세포암 치료의 효과를 높이고 부작용을 줄일 수 있는 맞춤형 치료법을 개발할 수 있게 되었습니다. 인공지능(AI)과 머신러닝의 통합은 새로운 치료 후보물질의 발견과 임상시험 설계의 최적화를 가속화하여 신약 시장 출시 시간을 단축하고 있습니다. 또한, 조기 발견과 조기 치료의 이점에 대한 환자와 의료진의 인식이 높아지면서 첨단 치료법의 채택을 촉진하고 있습니다. 더 많은 국가들이 의료 인프라를 개선하고 혁신적인 치료법에 대한 접근성을 향상시킴에 따라 간세포암 치료제에 대한 수요는 증가할 것으로 예상됩니다. 이러한 요인은 지속적인 혁신과 함께 간세포암 치료제 시장의 성장을 가속하는 요인으로 작용하고 있습니다.

조사 대상 기업 사례(51개사)

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Eisai Co.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Hepion Pharmaceuticals
  • ImmunoPhotonics
  • Imvax
  • Merck & Co.
  • Novartis AG
  • RayzeBio
  • SillaJen Biotherapeutics
  • TriSalus Life Sciences
  • Blepharitis Drugs

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.09.20

Global Hepatocellular Carcinoma Drugs Market to Reach US$1.7 Billion by 2030

The global market for Hepatocellular Carcinoma Drugs estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Chemotherapy Treatment, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$664.8 Million by the end of the analysis period. Growth in the Brachytherapy Treatment segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$297.4 Million While China is Forecast to Grow at 10.1% CAGR

The Hepatocellular Carcinoma Drugs market in the U.S. is estimated at US$297.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$358.6 Million by the year 2030 trailing a CAGR of 10.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Hepatocellular Carcinoma Drugs Market - Key Trends and Drivers Summarized

What Are the Latest Developments in Hepatocellular Carcinoma Drugs?

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, has seen significant advancements in drug development over recent years, offering new hope to patients. Traditional treatment options for HCC were largely limited to surgery, liver transplantation, and localized therapies like radiofrequency ablation or transarterial chemoembolization. However, the advent of targeted therapies and immunotherapies has revolutionized the treatment landscape. Sorafenib, the first FDA-approved targeted therapy for HCC, marked a turning point by inhibiting tumor cell proliferation and angiogenesis. Since then, newer agents like lenvatinib, regorafenib, and cabozantinib have emerged, offering improved survival benefits and tolerability. In addition, the introduction of immune checkpoint inhibitors, such as nivolumab and pembrolizumab, has further expanded treatment options, particularly for patients who are not candidates for surgery or who have advanced-stage disease. These therapies work by enhancing the body's immune response against cancer cells, offering a novel mechanism of action that complements traditional approaches. The continuous evolution of HCC drug therapies underscores the importance of ongoing research and clinical trials in improving patient outcomes.

How Are Combination Therapies Changing the Treatment Paradigm for HCC?

Combination therapies are increasingly becoming the cornerstone of HCC treatment, driven by the recognition that single-agent therapies often face limitations in efficacy and durability. Combining targeted therapies with immunotherapies has shown promising results, particularly in advanced stages of the disease where options were previously limited. For example, the combination of atezolizumab, an immune checkpoint inhibitor, with bevacizumab, an anti-VEGF antibody, has demonstrated superior efficacy compared to sorafenib, setting a new standard of care in first-line treatment for unresectable HCC. This combination exploits the synergistic effects of immune modulation and angiogenesis inhibition, leading to prolonged survival and better control of disease progression. Similarly, ongoing clinical trials are exploring various other combinations, including dual checkpoint inhibition (e.g., nivolumab with ipilimumab) and the use of tyrosine kinase inhibitors alongside immune checkpoint inhibitors. The success of these combination strategies highlights the potential to overcome resistance mechanisms and achieve more durable responses, particularly in a disease as complex and heterogeneous as HCC. As research continues, combination therapies are likely to further reshape the therapeutic landscape, offering more personalized and effective treatment options for HCC patients.

What Are the Challenges and Opportunities in Developing HCC Drugs?

The development of drugs for HCC faces several challenges, yet it also presents significant opportunities for innovation and advancement. One of the primary challenges is the heterogeneity of the disease, as HCC can arise from various underlying liver conditions, such as hepatitis B or C infection, non-alcoholic steatohepatitis (NASH), or cirrhosis, each of which may respond differently to treatment. This diversity makes it difficult to develop a one-size-fits-all therapy and necessitates a more personalized approach to treatment. Moreover, the liver's central role in drug metabolism poses additional challenges in developing therapies that are both effective and safe, as patients with HCC often have compromised liver function. Despite these challenges, there are significant opportunities for innovation, particularly in the areas of biomarker discovery and precision medicine. Identifying molecular markers that predict response to therapy could enable more targeted treatment approaches, improving efficacy and minimizing side effects. Additionally, the growing interest in harnessing the gut-liver axis and exploring the role of the microbiome in HCC progression presents new avenues for therapeutic intervention. These challenges and opportunities underscore the need for a multidisciplinary approach to HCC drug development, integrating advances in genomics, immunology, and pharmacology.

What Is Driving Growth in the Hepatocellular Carcinoma Drugs Market?

The growth in the hepatocellular carcinoma drugs market is driven by several factors that reflect advancements in medical technology, shifts in healthcare practices, and changing patient demographics. One of the primary drivers is the increasing incidence of HCC globally, fueled by rising rates of chronic liver diseases such as hepatitis C, hepatitis B, and non-alcoholic fatty liver disease (NAFLD). This growing patient population has heightened the demand for effective treatment options. Additionally, the rapid advancement in biotechnology and the development of novel drug delivery systems have enabled the creation of more targeted and personalized therapies, enhancing the effectiveness and reducing the side effects of HCC treatments. The integration of artificial intelligence (AI) and machine learning in drug development is also accelerating the discovery of new therapeutic candidates and optimizing clinical trial designs, thereby shortening the time to market for new drugs. Furthermore, increasing awareness among patients and healthcare providers about the benefits of early detection and treatment is driving the adoption of advanced therapies. As more countries improve their healthcare infrastructure and increase access to innovative treatments, the demand for HCC drugs is expected to grow. These factors, combined with the ongoing innovation in drug development, are propelling the expansion of the hepatocellular carcinoma drugs market.

Select Competitors (Total 51 Featured) -

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Hepion Pharmaceuticals
  • ImmunoPhotonics
  • Imvax
  • Merck & Co., Inc.
  • Novartis AG
  • RayzeBio
  • SillaJen Biotherapeutics
  • TriSalus Life Sciences
  • Blepharitis Drugs

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Hepatocellular Carcinoma Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Liver Cancer Expands Addressable Market Opportunity for Hepatocellular Carcinoma Drugs
    • Advancements in Targeted Therapies Propel Growth in Precision Medicine for Hepatocellular Carcinoma
    • Increasing Adoption of Immunotherapy Strengthens Business Case for Novel Hepatocellular Carcinoma Treatments
    • Growing Focus on Combination Therapies Spurs Growth in Multi-Modal Treatment Approaches
    • Emergence of Biomarker-Based Therapies Throws the Spotlight on Personalized Hepatocellular Carcinoma Drug Development
    • Challenges in Drug Resistance and Recurrence Present Opportunities for Innovation in Next-Generation Therapies
    • Expansion of Clinical Trials and Research Initiatives Creates New Pathways for Hepatocellular Carcinoma Drug Approvals
    • Increasing Prevalence of Risk Factors Such as Hepatitis and Cirrhosis Expands the Market for Preventive and Therapeutic Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatocellular Carcinoma Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Brachytherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Brachytherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Brachytherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Local Ablation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Local Ablation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Local Ablation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • CHINA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • INDIA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제